Navigation Links
Trillium adds industry veteran Dr. Mike Gresser to its Board of Directors
Date:1/28/2010

TORONTO, Jan. 28 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that Dr. Michael Gresser has joined its Board of Directors as an independent director. Trillium Chairman Dr. Michael Moore commented: "It is a great pleasure to welcome such an experienced biotech executive as Dr. Gresser to the Board. His widely acclaimed contribution to drug discovery and development in the immune-inflammatory field will greatly benefit Trillium."

Trillium's overall strategy is to build and solidify its reputation as a premier immunology company, by creating a broad and innovative pipeline of proprietary biologic product opportunities. The company has already captured long-term value and de-risked some of its projects through a series of partnerships with multinational companies. Trillium also has a demonstrated ability to identify and access promising early-stage technologies, and is on track to announce the in-licensing of additional projects in the near future, strengthening its existing immunology franchise.

"We are building a leading company in the immunology space. With his years of drug development experience, Dr. Gresser is an ideal director to assist in achieving Trillium's goals", added Dr. Michael Cross, a member of Trillium's Board of Directors and Partner, GrowthWorks Capital. "In building Trillium, our focus is on delivering outstanding science and creating strong alliances with world-class partners. Dr. Gresser's substantial background and success in these areas will be of great value as we move forward."

About Dr. Michael Gresser:

Dr. Gresser received his PhD in Biochemistry in 1976 and after postdoctoral studies at the Molecular Biology Institute at UCLA he joined the Department of Chemistry at Simon Fraser University in Burnaby, British Columbia. In 1988 Dr. Gresser Joined the Merck Frosst Center for Therapeutic Research in Kirkland, Quebec as Director of Biochemistry. Over the next twelve years he progressed to Executive Director of Biochemistry and Molecular Biology and his team worked on a variety of small molecule drug discovery programs, resulting in the introduction of numerous molecules into clinical trials. Two of these molecules, Singulair and Vioxx, became products. In 2000 Dr. Gresser joined Amgen Inc. in Thousand Oaks, California, as Vice President, Research Inflammation, where he remained until April, 2006. His team at Amgen worked on many molecular targets, introducing numerous small molecules, human antibodies, and other proteins into development. Currently Dr. Gresser serves as CSO of Oxford BioTherapeutics, and is also Visiting Scholar at the Molecular Biology Institute at UCLA.

About Trillium:

Trillium Therapeutics Inc. is a private biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as autoimmune and inflammatory disorders, as well as cancer. The company's lead program, TTI-1612, is a recombinant growth factor that is being developed for the treatment of interstitial cystitis (IC) and the prevention of necrotizing enterocolitis (NEC). Trillium has broad portfolio preclinical immunology programs, including two that target the CD200 immunoregulatory axis; a CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases. In addition, the company has an FcRIIa-specific humanized monoclonal antibody in development for treatment of immune complex-mediated inflammatory diseases.

Trillium has a broad network of external academic and industry R&D collaborations, including several license agreements with major US biotechnology companies. The Company is supported by three premier venture capital investors: Vengrowth Private Equity Partners, Growthworks Capital and BDC Capital.

SOURCE Trillium Therapeutics Inc.


'/>"/>
SOURCE Trillium Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Trillium and Biogen Idec enter into global license agreement
2. Trillium Strengthens its Board of Directors
3. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
4. Biodefense Industry Response to New WMD Report Card
5. New Industry Research Identifies "Operational Gap" in Clinical Trial Portfolio Management
6. A Recovery Act Success Story: NIH Funding of Biomedical Innovation Is Creating Jobs, Fueling Industry Growth, and Helping Reduce Long-term Health Care Costs
7. Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer
8. Ethanol Blend Reduction in Brazil Makes Sense Provided 90-Day Deadline is Respected, Says Brazilian Sugarcane Industry Association
9. Microbix And Therapure Biopharma Form Partnership To Expand Water-Based Supplies To The Pharma Industry
10. Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010
11. Goble & Associates Creative Work Awarded at Advertising Industry Competitions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
Breaking Biology News(10 mins):